We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aldeyra Therapeutics Inc | NASDAQ:ALDX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -1.19% | 4.16 | 1.70 | 37.35 | 4.29 | 4.075 | 4.23 | 319,625 | 05:00:03 |
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the company will host a conference call on Thursday, March 12, 2020, at 8:00 a.m. ET to discuss financial results for the quarter and year ended December 31, 2019 and provide a corporate update.
The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 9984588. A live webcast of the conference call will also be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com.
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.
About Aldeyra Therapeutics Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and SjĂgren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200305005254/en/
Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300 ALDX@investorrelations.com
1 Year Aldeyra Therapeutics Chart |
1 Month Aldeyra Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions